NCT07054632 - Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

August 13, 2025

Study Completion Date

August 31, 2029

Conditions

Inherited Retinal Dystrophy Associated With RPE65 Mutations

Interventions

GENETIC

LX101

Subretinal administration of LX101 to the study eye

Trial Locations (4)

Zhongshan Ophthalmic Center, Sun Yat sen University, Guangzhou

Southwest Hospital of AMU, Chongqing

Shanghai General Hospital, Shanghai

Tianjin Medical University Ophthalmology Hospital, Tianjin